Eli Lilly (NYSE:LLY) and licensor Incyte (NASDAQ:INCY) announce positive results from another Phase 3 clinical trial, BREEZE-AD5, evaluating two strengths of oral JAK inhibitor baricitinib in adults with moderate-to-severe atopic dermatitis (AD).
The 1 mg dose failed to hit the primary endpoint
of a statistically significant proportion of patients achieving at least
a 75% improvement in AD (EASI75) at week 16 versus placebo.
The 2 mg dose was successful. 29.5% (n=43/146) of
treated patients achieved EASI75 compared to 8.2% (n=12/147) in the
control arm (p=0.001).
No new safety signals were observed.
Complete results will be submitted for presentation at future medical conferences and publication.
Three previous late-stage studies, BREEZE-AD1, AD2 and AD7, were also successful.
Lilly recently filed a marketing Europe. It expects to submit applications in the U.S. and Japan this year.
LLY is up 1% premarket.
https://seekingalpha.com/news/3536233-lilly-baricitinib-successful-in-fourth-late-stage-dermatitis-study
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.